SEC Comment Letter 0000000000-24-012682 to VOLITIONRX LTD (VNRX)
VOLITIONRX LTD
Date: Nov. 15, 2024 · CIK: 0000093314 · Accession: 0000000000-24-012682
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283088
Letter
November 15, 2024 Cameron Reynolds Chief Executive Officer VolitionRx Limited 1489 West Warm Springs Road, Suite 110 Henderson, NV 89014 Re:VolitionRx Limited Registration Statement on Form S-3 Filed November 8, 2024 File No. 333-283088 Dear Cameron Reynolds: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Marc Alcser
Show Raw Text
November 15, 2024
Cameron Reynolds
Chief Executive Officer
VolitionRx Limited
1489 West Warm Springs Road, Suite 110
Henderson, NV 89014
Re:VolitionRx Limited
Registration Statement on Form S-3
Filed November 8, 2024
File No. 333-283088
Dear Cameron Reynolds:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Marc Alcser